JO3753B1 - قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه - Google Patents

قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Info

Publication number
JO3753B1
JO3753B1 JOP/2012/0301A JOP20120301A JO3753B1 JO 3753 B1 JO3753 B1 JO 3753B1 JO P20120301 A JOP20120301 A JO P20120301A JO 3753 B1 JO3753 B1 JO 3753B1
Authority
JO
Jordan
Prior art keywords
quinolin
thiophen
piperazin
benzo
butoxy
Prior art date
Application number
JOP/2012/0301A
Other languages
English (en)
Inventor
Inoue Yoshiharu
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48081918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3753(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JO3753B1 publication Critical patent/JO3753B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Physiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Supply Of Fluid Materials To The Packaging Location (AREA)
  • Basic Packing Technique (AREA)

Abstract

يتعلق ذلك الاختراع بقرص يتضمن، كمكون أساسي نشط، 7-<span dir="LTR">]</span>4-(4-بنزو<span dir="LTR"> [b] </span>ثيوفين-4-يل-بيبرازين-1-يل)بيوتوكسي<span dir="LTR">[</span>-1<span dir="LTR">H</span>-كينولين-2- أون أو ملح منه، يكون له قابلية تقتت ممتازة، استقرار أثناء التخزين و الاستقرار الضوئي. <span dir="RTL">يحتوي القرص الخاص بالاختراع الحالي على 7-</span>]<span dir="RTL">4-(4- بنزو </span>[b] <span dir="RTL">ثيوفين-4-يل- بيبرازين-1-يل) بيوتوكسي</span>[<span dir="RTL">-1</span>H<span dir="RTL">-كينولين-2- أون أو ملح منه كمكون أساسي نش، و يحتوي أيضا على عامل تغطية تتضمن لاكتوز، نشا الذرة، بلورة سيلولوز دقيقة و سواغات مشابهة؛ هيدروكسي بروبيل سيلولوز منخفض الاستبدال، كروسكارميلوز صوديوم، صوديوم كربوكسيل ميثيل نشا و مواد مفتتة مشابهة؛ هيدروكسي بروبيل سيلولوز و مواد رابطو مشابهة؛ ميلوز فائق؛تلك؛ أكسيد تيتانيوم؛ مواد ملونة؛ و ما شابه ذلك.</span>
JOP/2012/0301A 2011-10-14 2012-10-04 قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه JO3753B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2011227057 2011-10-14

Publications (1)

Publication Number Publication Date
JO3753B1 true JO3753B1 (ar) 2021-01-31

Family

ID=48081918

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0301A JO3753B1 (ar) 2011-10-14 2012-10-04 قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Country Status (34)

Country Link
US (9) US20140234417A1 (ar)
EP (1) EP2767285B2 (ar)
JP (2) JP6084161B2 (ar)
KR (1) KR102072371B1 (ar)
CN (2) CN103889425B (ar)
AP (1) AP2014007564A0 (ar)
AR (1) AR088319A1 (ar)
AU (1) AU2012321723C1 (ar)
BR (1) BR112014008603A2 (ar)
CA (1) CA2851588C (ar)
CL (1) CL2014000909A1 (ar)
CO (1) CO6950480A2 (ar)
CY (1) CY1122460T1 (ar)
DK (1) DK2767285T4 (ar)
EA (1) EA032930B1 (ar)
ES (1) ES2762479T5 (ar)
FI (1) FI2767285T4 (ar)
HR (1) HRP20200037T4 (ar)
HU (1) HUE047493T2 (ar)
IL (1) IL231513B (ar)
IN (1) IN2014DN02055A (ar)
JO (1) JO3753B1 (ar)
LT (1) LT2767285T (ar)
MX (1) MX376092B (ar)
MY (1) MY173370A (ar)
PH (1) PH12014500607A1 (ar)
PL (1) PL2767285T5 (ar)
PT (1) PT2767285T (ar)
SG (2) SG10201608412SA (ar)
SI (1) SI2767285T2 (ar)
TW (1) TWI634908B (ar)
UA (1) UA114411C2 (ar)
WO (1) WO2013054872A1 (ar)
ZA (1) ZA201402333B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5936732B1 (ja) * 2015-03-05 2016-06-22 日本カラコン合同会社 フィルムコーティング組成物
CN105106142B (zh) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 一种含有依匹哌唑的冻干口服制剂及其制备方法
CN106994119A (zh) * 2016-01-22 2017-08-01 浙江华海药业股份有限公司 含有依匹哌唑或其盐的口腔崩解片及其制备方法
BR112018015369A2 (pt) * 2016-02-19 2018-12-18 Jiangsu Hengrui Medicine Co., Ltd. composição farmacêutica contendo inibidor de jak cinase ou sal farmaceuticamente aceitável do mesmo
CN109414051A (zh) * 2016-06-28 2019-03-01 株式会社日本抗菌总和研究所 赋形剂和片剂
JP7060878B2 (ja) * 2016-07-27 2022-04-27 日本臓器製薬株式会社 メトトレキサート含有フィルムコーティング錠
WO2018033484A1 (en) 2016-08-16 2018-02-22 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
WO2018033481A1 (en) 2016-08-16 2018-02-22 H E X A L Aktiengesellschaft Immediate release tablet of a benzothiophene compound
CN106496206A (zh) * 2016-08-31 2017-03-15 安徽省润生医药股份有限公司 一种依匹哌唑新的制备方法
US10919898B2 (en) * 2017-02-23 2021-02-16 Boehringer Ingelheim International Gmbh Medical use of compound III
JP7166754B2 (ja) 2017-11-22 2022-11-08 沢井製薬株式会社 ダサチニブ無水物含有製剤
EP3501506B1 (en) 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
EP3545950A1 (en) * 2018-03-26 2019-10-02 Adamed sp. z o.o. Pharmaceutical composition comprising brexpiprazole
JPWO2021029020A1 (ar) * 2019-08-13 2021-02-18
WO2021095092A1 (ja) * 2019-11-11 2021-05-20 大塚製薬株式会社 口腔内崩壊錠
CN112168794A (zh) * 2020-10-27 2021-01-05 浙江诺得药业有限公司 一种布瑞哌唑片的制备方法
TWI820674B (zh) * 2021-04-13 2023-11-01 大陸商上海雲晟研新生物科技有限公司 布瑞哌唑物口腔薄膜劑、其製備方法及用途
EP4374856A1 (en) 2022-11-23 2024-05-29 Sanovel Ilac Sanayi Ve Ticaret A.S. A process for tablets comprising brexpiprazole

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562375B1 (en) * 1999-08-04 2003-05-13 Yamanouchi Pharmaceuticals, Co., Ltd. Stable pharmaceutical composition for oral use
AU2002353659A1 (en) * 2001-12-18 2003-07-15 Synthon B.V. Simvastatin dosage forms
JP4584706B2 (ja) * 2002-05-03 2010-11-24 イスラエル インスティチュート フォー バイオロジカル リサーチ 中枢及び末梢神経系障害を治療するための方法及び組成物、並びにそれらに有用な新規の化合物
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
RU2358992C2 (ru) * 2003-06-09 2009-06-20 Дау Глобал Текнолоджиз Инк. Стабилизированные органоборановые инициаторы полимеризации и способные к полимеризации композиции
JP2006061067A (ja) * 2004-08-26 2006-03-09 Asahi Kasei Life & Living Corp 酸素インジケーター
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP1858514B1 (en) 2005-03-17 2014-11-26 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
DK1808164T3 (da) 2006-01-05 2009-04-20 Teva Pharma Vådgranuleringsmetode til fremstilling af farmaceutiske sammensætninger af aripiprazol
JP4806595B2 (ja) * 2006-07-05 2011-11-02 富士フイルム株式会社 固体撮像素子駆動装置及びデジタルカメラ
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
WO2008106059A1 (en) * 2007-02-26 2008-09-04 Merck & Co., Inc. Formulations for cathepsin k inhibitors
JP5432720B2 (ja) * 2007-03-13 2014-03-05 武田薬品工業株式会社 ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
KR20100099113A (ko) * 2007-10-12 2010-09-10 아스트라제네카 아베 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
JP5463564B2 (ja) * 2009-05-22 2014-04-09 国立大学法人信州大学 耐熱性及び耐塩性セルラーゼ製剤
TR201000948A1 (tr) 2010-02-09 2011-08-22 Sanovel İlaç San.Ve Ti̇c.A.Ş. Aripiprazol formülasyonları.
TWI636784B (zh) 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
ES2606511T3 (es) 2011-04-06 2017-03-24 Biovaxim Limited Composiciones farmacéuticas para prevenir y/o tratar una enfermedad por VIH en seres humanos
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه

Also Published As

Publication number Publication date
JP2017088610A (ja) 2017-05-25
IL231513A0 (en) 2014-04-30
AU2012321723A1 (en) 2014-05-15
EP2767285A4 (en) 2015-03-11
CN103889425A (zh) 2014-06-25
EP2767285A1 (en) 2014-08-20
HRP20200037T1 (hr) 2020-03-20
JP6084161B2 (ja) 2017-02-22
CN103889425B (zh) 2018-08-03
MX2014004135A (es) 2014-07-24
DK2767285T4 (da) 2025-04-22
DK2767285T3 (da) 2020-01-27
US20220331311A1 (en) 2022-10-20
MX376092B (es) 2025-03-07
US20180008600A1 (en) 2018-01-11
SI2767285T2 (sl) 2025-06-30
ES2762479T3 (es) 2020-05-25
CL2014000909A1 (es) 2014-11-21
BR112014008603A2 (pt) 2017-04-18
CN107397730A (zh) 2017-11-28
EA032930B1 (ru) 2019-08-30
KR20140075754A (ko) 2014-06-19
CY1122460T1 (el) 2021-01-27
HRP20200037T4 (hr) 2025-05-23
US10307419B2 (en) 2019-06-04
LT2767285T (lt) 2020-02-10
AU2012321723B2 (en) 2017-07-20
WO2013054872A1 (ja) 2013-04-18
AR088319A1 (es) 2014-05-28
CA2851588C (en) 2019-07-02
KR102072371B1 (ko) 2020-02-03
IL231513B (en) 2020-01-30
SI2767285T1 (sl) 2020-03-31
EP2767285B2 (en) 2025-02-19
US20260207583A1 (en) 2026-07-23
SG2014013783A (en) 2014-06-27
NZ622639A (en) 2015-11-27
PT2767285T (pt) 2020-01-21
AU2012321723C1 (en) 2017-11-02
TWI634908B (zh) 2018-09-11
JPWO2013054872A1 (ja) 2015-03-30
PH12014500607A1 (en) 2014-04-21
CO6950480A2 (es) 2014-05-20
US20170165258A1 (en) 2017-06-15
FI2767285T4 (fi) 2025-05-08
US20160158227A1 (en) 2016-06-09
CA2851588A1 (en) 2013-04-18
US20240277703A1 (en) 2024-08-22
ES2762479T5 (en) 2025-05-30
PL2767285T3 (pl) 2020-04-30
PL2767285T5 (pl) 2025-06-02
EP2767285B1 (en) 2019-11-27
EA201490783A1 (ru) 2014-07-30
SG10201608412SA (en) 2016-12-29
US20140234417A1 (en) 2014-08-21
IN2014DN02055A (ar) 2015-05-15
US20190240215A1 (en) 2019-08-08
MY173370A (en) 2020-01-21
US20210023078A1 (en) 2021-01-28
ZA201402333B (en) 2015-07-29
AP2014007564A0 (en) 2014-04-30
TW201318651A (zh) 2013-05-16
UA114411C2 (uk) 2017-06-12
HUE047493T2 (hu) 2020-04-28

Similar Documents

Publication Publication Date Title
PH12014500607A1 (en) Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1h-quinolin-2-one or a salt thereof
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
WO2011093672A3 (en) Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
MY183536A (en) Pharmaceutical compositions comprising azd9291
PH12014501504A1 (en) THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASES
WO2012064973A3 (en) Heterocyclic compounds and uses thereof
RU2014143536A (ru) Фармацевтическая композиция, содержащая омелсартана медоксомил и розувастатин или его соль
EP3626253A3 (en) Stable formulations of linaclotide
MY161162A (en) Immunosuppressant formulations
PH12012502153A1 (en) Enteric tablet
PH12019501288A1 (en) Novel preparation containing benzimidazole derivative
PH12019501873A1 (en) Pharmaceutical composition
JP2016108327A5 (ar)
MX2015008502A (es) Sales sulfato de n-(3-(4-(3-(diisobutilamino)propil)piperazin-1-il )propil)-1h-benzo [d]imidazol-2-amina, preparación y uso de las mismas.
PL2647637T3 (pl) Pochodna purynylopirydynyloamino-2,4-dlfluorofenylo-sulfonamidu, jej farmaceutycznie dopuszczalna sól, sposób jej wytwarzania oraz zawierająca ją jako składnik aktywny kompozycja farmaceutyczna o aktywności hamującej kinazę Raf
TN2014000177A1 (en) Immediate release 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-[5-(4-methyl- 1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide formulation
WO2014030172A3 (en) Pharmaceutical formulations of rufinamide
MY195591A (en) A Fast Disintegrating Pharmaceutical Composition
TH148341A (th) ยาเม็ดซึ่งประกอบรวมด้วย 7-[4-(4-เบนโซ[b]ไธโอเฟน-4-อิล-ไพเพอราซิน-1-อิล)บิวทอกซิ]-1H-ควิโนลิน-2-โอน หรือเกลือของมัน
UA103558C2 (ru) Таблетка пролонгированного высвобождения, которая содержит теобромин
PH12012501798A1 (en) Use of dronedarone or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for administration shortly after amiodarone discontinuation
TH168085A (th) ยาเตรียมของการรวมกันทางเภสัชกรรมที่ประกอบด้วยตัวยับยั้งเอนไซม์เอชเอ็มจี-โคเอ รีดัคเตส และ ตัวยับยั้งการดูดซึมคลอเลสเตอรอล
HK1189574A (en) Heterocyclic compounds and uses thereof
UA47107U (en) Drug formulation in tablet form possessing mucolytic and antihistamine properties
UA91283U (uk) Фармацевтичний продукт, що має виражену антигестагенну дію